Cardiorenal comorbidity
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old, regardless of gender; 2. Individuals meeting any of the following combinations are defined as the "cardiorenal comorbidity" population: Concurrent presence of CKD and CVD; Subsequent development of CVD in patients with CKD (CKD?CVD); New-onset AKI/AKD or CKD following a cardiovascular event (CVD?CKD). 3. In the prospective follow-up population, those who have not yet developed comorbidity involving the other system are also included to observe the incidence process of new-onset "cardiorenal comorbidity" and its predictive factors.
Exclusion criteria
Exclusion criteria: 1. Patients with newly diagnosed primary or secondary tumors within 6 months before enrollment, as well as those undergoing anti-tumor treatment; 2. Severe liver dysfunction (bilirubin or transaminase exceeding twice the upper limit of normal) or severe cerebrovascular disease; 3. Patients with urinary system malformations; 4. Female subjects of childbearing age who are positive for pregnancy test, pregnant, lactating, or those with plans for pregnancy or lactation during the study or who have not taken effective contraceptive measures; 5. Participation in other clinical studies within 1 month before the start of this study; 6. Patients with poor compliance who are deemed unsuitable for enrollment by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endpoint events such as rehospitalization and death; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical characteristics and disease course information;Dynamic indicators such as blood biochemistry and urine tests (no additional blood samples required);TCM four diagnostic information and syndrome differentiation (conducted in some departments); | — |
Countries
China
Contacts
Zhongshan Hospital, Fudan University